Results 81 to 90 of about 52,475 (270)

Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, EarlyView.
The diagnosis of atrial cardiomyopathy (AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. The diagnostic cut‐points presented are for standard electrocardiogram and echocardiogram studies (see Figure 1 for further detail).
Jerremy Weerts, Otilia Țica, Julia Aranyo, Christian Basile, Angelina Borizanova‐Petkova, Josip Andjelo Borovac, Massimiliano Camilli, Martin Eichenlaub, Emiliano Fiori, Tim Van Loon, Coenraad Withaar, Diana Zakarkaitė, Matthias D. Zink, Marianna Adamo, Alberto Aimo, Elena Arbelo, Felipe Bisbal Van Bylen, Dimitrios T. Farmakis, Dobromir Dobrev, Jelena Čelutkienė, Michael Böhm, Andrew Coats, Marco Metra, Giuseppe Rosano, Frank Ruschitzka, Antoni Bayes‐Genis, Dipak Kotecha   +26 more
wiley   +1 more source

NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]

, 2016
Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne, Hicks, Tim, Stewart, Fiona   +2 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia

ClinicoEconomics and Outcomes Research, 2021
Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi ...
Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, Ambaye AS   +5 more
doaj  

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE [PDF]

, 2015
Introduction: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been
Clawson, S, Cohen, H, Doré, CJ, Hunt, BJ, Isenberg, D, Khamashta, M, Muirhead, N, RAPS Trial Protocol Collaborators, .   +7 more
core   +1 more source

Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (PBPK) models have been utilized extensively for initial dosing regimen and sampling ...
James W. T. Yates, Michael Zientek, Kunal S. Taskar, Wen Lin, Tycho Heimbach, Stefan Willmann, Jessica Rehmel, Neil Parrott, Michael Hanley, Justine Badee, Yuan Chen, Susan Cole, Loeckie De Zwart, Sebastian Haertter, Rongrong Jiang, Masakatsu Kotsuma, Guiqing Liang, Yu‐Wei Lin, Jing Liu, Ying Ou, Juliane Rascher, Naveed A. Shaik, Jan Wahlstrom, Xiaofeng Wang, Guangqing Xiao, Ka Lai Yee, S. Y. Amy Cheung   +26 more
wiley   +1 more source

Case report: Severe hepatopathy following rivaroxaban administration in a dog

Frontiers in Veterinary Science
Rivaroxaban, a specific factor Xa inhibitor and commonly utilized anticoagulant, has been known to cause hepatotoxicity and liver failure in humans. Although rivaroxaban is frequently used in veterinary medicine, hepatotoxicity has not been previously ...
Allison P. Mosichuk, Candace Wimbish, Kristen Poplawski, Adam Birkenheuer, Karyn Harrell, Kursten V. Pierce   +5 more
doaj   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis and cost-effectiveness analysis [PDF]

, 2017
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH):
Sterne, Jonathan Ac, Bodalia, Pritesh N, Bryden, Peter A, Davies, Philippa A, López-López, Jose A, Okoli, George N, Thom, Howard Hz, Caldwell, Deborah M, Dias, Sofia, Eaton, Diane, Higgins, Julian Pt, Hollingworth, William, Salisbury, Chris, Savović, Jelena, Sofat, Reecha, Stephens-Boal, Annya, Welton, Nicky J, Hingorani, Aroon D   +17 more
core   +3 more sources